{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-26-000502","form_type":"8-K","ticker":"LNAI","cik":"0001527728","company_name":"Lunai Bioworks Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.335425+00:00","generated_at":"2026-05-15T08:22:16.979309+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lunai Bioworks enters $20M strategic acquisition; exchanges $828K debt for equity","bullets":["Debt exchange: $828,770.14 principal and interest canceled for 3,909,293 shares at $0.21/share and warrants exercisable at $0.21 through 2036.","Enters $20M strategic transaction for BBB delivery platform and CNS Alzheimer's drug assets from Clemann Group.","Transaction structured as Series B Convertible Preferred at fixed $1.50 conversion price; no variable pricing or reset provisions.","Platform enables compounds to cross BBB, remain inactive systemically, and activate in the brain; targets acetylcholinesterase pathways.","CEO David Weinstein says transaction is a 'step-change' for CNS delivery capabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000502","json":"https://secwatch.observer/filing/0001731122-26-000502.json","markdown":"https://secwatch.observer/filing/0001731122-26-000502.md","text":"https://secwatch.observer/filing/0001731122-26-000502.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/0001731122-26-000502-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/e7507_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:22:16.979309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5136c380c6a527e30872c8ff55c983bf723b4a71","claim":"Lunai Bioworks Inc. entered into Debt Exchange Agreements with three of the Company’s holders of secured promissory notes valued at $828,770.14 (effective 2026-03-24).","evidence_excerpt":"On March 24, 2026, Lunai Bioworks, Inc. (the “Company”) entered into separate debt exchange agreements (collectively, the “Debt Exchange Agreements”) with three of the Company’s holders (each a “Holder”) of secured promissory notes (the “Investor Notes”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/0001731122-26-000502-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"three of the Company’s holders of secured promissory notes"},{"label":"Value","value":"$828,770.14"},{"label":"Effective","value":"2026-03-24"}]},{"claim_id":"bf4dd7b3413ce5b0f64e1f312e537d8c921b1377","claim":"Lunai Bioworks Inc. entered into Acquisition Agreement with Clemann Group, SAS valued at $20.0 million (effective 2026-03-26).","evidence_excerpt":"On March 26, 2026, the Company entered into a binding agreement (the “Acquisition Agreement”) with Clemann Group, SAS, or its assignee (the “Seller”), pursuant to which the Company agreed to acquire certain blood-brain barrier delivery technology and central nervous system Alzheimer’s drug assets (the “Transaction”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/0001731122-26-000502-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Clemann Group, SAS"},{"label":"Value","value":"$20.0 million"},{"label":"Effective","value":"2026-03-26"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}